Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Femasys Inc.

Tracked across 2 events · 12 articles · First seen Aug 07, 2026 · Last active Aug 19, 2026

Sentiment
45
Attention
3
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 10
Business
Impact: Femasys is the issuer of the private placement, raising $30 million with potential additional proceeds. The financing strengthens its balance sheet and supports its business plan, but the stock price declined due to dilution.
Aug 07, 2026 · 6 articles
3 80
Regulatory
Impact: Femasys is the developer of FemBloc and the recipient of the FDA's approval of the modular PMA pathway. This approval is a major step toward U.S. commercialization, positively impacting the company's prospects and stock price.
Aug 19, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Femasys Inc. live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.